These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34019025)

  • 1. Cardiac Toxicity: Using Angiotensin-Converting Enzyme Inhibitors to Prevent Anthracycline-Induced Left Ventricular Dysfunction and Cardiomyopathy.
    Kobza C
    Clin J Oncol Nurs; 2021 Jun; 25(3):259-266. PubMed ID: 34019025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anthracycline-induced cardiomyopathy].
    Roul G; Cohen C; Lieber A
    Presse Med; 2009 Jun; 38(6):987-94. PubMed ID: 19423276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy.
    Janbabai G; Nabati M; Faghihinia M; Azizi S; Borhani S; Yazdani J
    Cardiovasc Toxicol; 2017 Apr; 17(2):130-139. PubMed ID: 27003392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cardioprotection in women with neoplastic disease].
    Cardinale D; Colombo A; Bacchiani G
    G Ital Cardiol (Rome); 2012 Jun; 13(6):461-8. PubMed ID: 22622126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.
    Gujral DM; Lloyd G; Bhattacharyya S
    Breast; 2018 Feb; 37():64-71. PubMed ID: 29101824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of anthracycline and trastuzumab-induced decline in left ventricular ejection fraction with angiotensin-converting enzyme inhibitors or angiotensin receptor blocker: a narrative systematic review of randomised controlled trials.
    Lee S; Alsamarrai A; Xiao A; Wang TKM
    Intern Med J; 2024 Aug; 54(8):1254-1263. PubMed ID: 38874281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic prevention of anthracycline-induced cardiomyopathy.
    Maradia K; Guglin M
    Cardiol Rev; 2009; 17(5):243-52. PubMed ID: 19690476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthracycline-induced cardiomyopathy.
    Fisher NG; Marshall AJ
    Postgrad Med J; 1999 May; 75(883):265-8. PubMed ID: 10533628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
    Henriksen PA; Hall P; Oikonomidou O; MacPherson IR; Maclean M; Lewis S; McVicars H; Broom A; Scott F; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Payne JR; Newby DE; Mills NL; Lang NN
    Circ Heart Fail; 2022 Jul; 15(7):e009445. PubMed ID: 35766037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
    Ghasemi K; Vaseghi G; Mansourian M
    J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of afterload reduction in the prevention of late anthracycline cardiomyopathy.
    Silber JH
    Pediatr Blood Cancer; 2005 Jun; 44(7):607-13. PubMed ID: 15795884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
    Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
    J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ACE inhibitors in the treatment of ventricular dysfunction caused by cardiotoxic cytostatics].
    Mladosievicová B
    Ceska Slov Farm; 2004 Mar; 53(2):55-60. PubMed ID: 15095572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity.
    Ohtani K; Fujino T; Ide T; Funakoshi K; Sakamoto I; Hiasa KI; Higo T; Kamezaki K; Akashi K; Tsutsui H
    Clin Res Cardiol; 2019 Jun; 108(6):600-611. PubMed ID: 30367208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
    Blanter JB; Frishman WH
    Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis.
    Yun S; Vincelette ND; Abraham I
    Postgrad Med J; 2015 Nov; 91(1081):627-33. PubMed ID: 26399268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cardioprotective treatment during adjuvant cancer therapy].
    Gulati G; Heck SL; Ree AH; Gravdehaug B; Røsjø H; Steine K; Bratland Å; Hoffmann P; Geisler J; Omland T
    Tidsskr Nor Laegeforen; 2013 Sep; 133(17):1832-6. PubMed ID: 24042297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.